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Metastasis is the principal cause of cancer death andmorbidity
inpatients affectedbycancer. Treatmentofmetastasis is oneof the
objective principals of the therapy against the cancer. The term of
oligometastases defines the presence of limited metastasis both
in the number (<5 nodules and <5 cm in total) in the location (1
organ). To themomentmany survivors of solitarymetastasis exist,
especially liver and pulmonary, advances in molecular oncology
and imaging have allowed a precocious diagnosis of the same.
The therapeutic options of the oligometastases can be different
form the surgical excision, the ablation with stereotactic radiosur-
gery to the target therapyor the immunotherapy: all theoptionsare
able to eradicate the lesions. Recently, the rapid development of
new technical, very more conform, what the Image-Guided Radia-
tion Therapy (IGRT) and the Intensity Modulated Radiation Ther-
apy (IMRT), have allowed the administration of few fractions with
high doses, highly tailored to the lesions. With concern the radio-
therapy, the oligometastases treatment involved numerous step:
target definition and localisation, treatment planning, verification.
evaluation anddelivery that ask for greater accuracyandprecision.
In conclusion, in the treatment of the oligometastasis the integra-
tion of different methodic therapeutics, using the spatial coopera-
tion, can represent the new frontier of care in the patients
affections from small number of metastasis.
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The Human Genome Project led to the discovery of DNA
sequence variants, the majority of them being SNPs and gene
amplifications. The potential influence of DNA variation on the
activity and/or adverse reaction of cancer chemotherapy are
being investigated. Pharmacogenetics and pharmacogenomics
are gaining momentum and their application to cancer treat-
ment is of high priority. The number of studies reporting a rela-
tionship between DNA sequence variants and cancer treatment
outcome are increasing in number. In particular, the following
associations were found: DPYD gene mutations and severe 5-
FU toxicity,1 EGFR mutations and responsiveness of NSCLC to
gefitinib,2 ERCC1 polymorphisms and severe drug toxicity in
NSCLC patients,3 genetic variants in the UGT1A1 gene and
severe neutropenia by irinotecan,4 MTHFR genotype and treat-
ment response in paediatric ALL,5 TS and MTHFR gene polymor-
phisms in normal tissue and 5-FU sensitivity,6 TPMT genotype
and early treatment response to 6-MP in childhood ALL7 and
CDA genotype and response to gemcitabine in NSCLC.8 The next
step in pharmacogenetic research should be the validation of
these findings in randomised prospective trials, specifically
designed to compare the outcome of treatment selected on
the basis of patient’s genotype (normal tissue versus tumour)
versus standard approach. In conclusion, the improvement in
genotyping technologies and the availability of a high-density
SNP maps, combined with efficient and cost-effective analytical
methods, open the possibility of fulfilling the promise of reduc-
ing the toxicity and personalise the treatment offered to cancer
patients.
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